NEW YORK (GenomeWeb News) – Caprotec Bioanalytics said today that it will collaborate with a division of Merck KGaA to identify protein and drug interactions using its mass spectrometry technology.
 
Under the agreement, Caprotec will use its Capture Compound Mass Spectrometry technology for a research project for Merck Serono. Berlin-based Caprotec will be paid research fees and milestone payments for product development, it said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.